Definium Therapeutics, Inc. (DFTX)
NASDAQ: DFTX · Real-Time Price · USD
21.27
+0.29 (1.38%)
Apr 28, 2026, 4:00 PM EDT - Market closed
Definium Therapeutics Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2019 |
| Cash & Equivalents | 257.84 | 273.74 | 99.7 | 142.14 | 133.54 | Upgrade
|
| Short-Term Investments | 153.76 | - | - | - | - | Upgrade
|
| Cash & Short-Term Investments | 411.59 | 273.74 | 99.7 | 142.14 | 133.54 | Upgrade
|
| Cash Growth | 50.36% | 174.55% | -29.86% | 6.44% | 66.73% | Upgrade
|
| Prepaid Expenses | 7.73 | 7.88 | 4.17 | 3.91 | 3.68 | Upgrade
|
| Total Current Assets | 419.32 | 281.62 | 103.87 | 146.06 | 137.22 | Upgrade
|
| Goodwill | 19.92 | 19.92 | 19.92 | 19.92 | 19.92 | Upgrade
|
| Other Intangible Assets | - | - | 0.53 | 3.69 | 6.87 | Upgrade
|
| Other Long-Term Assets | 0.86 | 0.61 | 0.22 | 0.33 | - | Upgrade
|
| Total Assets | 440.1 | 302.15 | 124.54 | 169.99 | 164 | Upgrade
|
| Accounts Payable | 5.35 | 2.01 | 4.14 | 2.11 | 4.18 | Upgrade
|
| Accrued Expenses | 20.45 | 12.83 | 11.63 | 5.88 | 6.23 | Upgrade
|
| Other Current Liabilities | 40.91 | 24.01 | 16.48 | 9.9 | - | Upgrade
|
| Total Current Liabilities | 66.7 | 38.85 | 32.25 | 17.89 | 10.41 | Upgrade
|
| Long-Term Debt | 40.58 | 21.85 | 14.13 | - | - | Upgrade
|
| Other Long-Term Liabilities | 0.5 | - | 0.03 | 1.18 | 1.93 | Upgrade
|
| Total Liabilities | 107.77 | 60.7 | 46.41 | 19.08 | 12.34 | Upgrade
|
| Additional Paid-In Capital | 913.91 | 639.51 | 367.99 | 344.76 | 288.29 | Upgrade
|
| Retained Earnings | -582.67 | -398.88 | -290.2 | -194.47 | -137.67 | Upgrade
|
| Comprehensive Income & Other | 1.09 | 0.82 | 0.34 | 0.63 | 1.05 | Upgrade
|
| Shareholders' Equity | 332.33 | 241.45 | 78.13 | 150.92 | 151.66 | Upgrade
|
| Total Liabilities & Equity | 440.1 | 302.15 | 124.54 | 169.99 | 164 | Upgrade
|
| Total Debt | 40.58 | 21.85 | 14.13 | - | - | Upgrade
|
| Net Cash (Debt) | 371.01 | 251.89 | 85.58 | 142.14 | 133.54 | Upgrade
|
| Net Cash Growth | 47.29% | 194.35% | -39.80% | 6.44% | 66.73% | Upgrade
|
| Net Cash Per Share | 4.15 | 3.57 | 2.19 | 4.61 | 4.88 | Upgrade
|
| Filing Date Shares Outstanding | 99.7 | 75.37 | 41.33 | 38.06 | 28.58 | Upgrade
|
| Total Common Shares Outstanding | 98.78 | 75.1 | 41.1 | 37.98 | 28.55 | Upgrade
|
| Working Capital | 352.62 | 242.77 | 71.63 | 128.16 | 126.81 | Upgrade
|
| Book Value Per Share | 3.36 | 3.21 | 1.90 | 3.97 | 5.31 | Upgrade
|
| Tangible Book Value | 312.41 | 221.53 | 57.69 | 127.31 | 124.88 | Upgrade
|
| Tangible Book Value Per Share | 3.16 | 2.95 | 1.40 | 3.35 | 4.37 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.